Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.12436 http://scihub22266oqcxt.onion/10.1111/bjh.12436 C4685467!4685467!23789936     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2013 ; 162 (4): 517-24 Nephropedia Template TP {{tp|p=23789936|t=2013. Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes |pdf=|usr=}}{{23789936}} gab.com Text Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=23789936 #FOAvip The multi-kinase inhibitor rigosertib (ON 01910.Na) induces mitotic arrest and apoptosis in myeloblasts, while sparing normal cells. The purpose of this study was to determine the pharmacokinetic profile, maximum-tolerated dose (MTD), safety, and clinical activity of an oral formulation of rigosertib in patients with myelodysplastic syndromes (MDS). For pharmacokinetic studies, patients received rigosertib in single escalating weekly doses. To determine the MTD, patient cohorts received escalating doses of rigosertib twice daily for 14 days of a 21-day cycle. Overall, 37 patients were treated. Rigosertib exposure increased with escalating oral doses. Mean absolute oral bioavailability ranged from 13.9% (fed) to 34.8% (fasting) in 12 patients treated at the 560 mg dose level. Dose-limiting toxicity (grade 3 dysuria and shortness of breath) occurred at the 700 mg b.i.d. dose. Five patients experienced grade 3 non-haematological toxicity, including symptoms of urothelial inflammation, hypotension and syncope, fatigue and abdominal pain. Encouraging signs of clinical activity included 2 bone marrow complete remissions in refractory anaemia with excess blasts type 1 patients previously treated with azacitidine. In addition, 4 patients each achieved transfusion independence and haematological improvements. In conclusion, oral rigosertib is bioavailable and well tolerated, and has clinical activity in patients with MDS. Twit Text FOAVip Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=23789936 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23789936 #FOAvip English Wikipedia <ref>{{Cite pmid|23789936}}</ref> Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes #MMPMID23789936 Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF Br J Haematol 2013[Aug]; 162 (4): 517-24 PMID23789936show ga The multi-kinase inhibitor rigosertib (ON 01910.Na) induces mitotic arrest and apoptosis in myeloblasts, while sparing normal cells. The purpose of this study was to determine the pharmacokinetic profile, maximum-tolerated dose (MTD), safety, and clinical activity of an oral formulation of rigosertib in patients with myelodysplastic syndromes (MDS). For pharmacokinetic studies, patients received rigosertib in single escalating weekly doses. To determine the MTD, patient cohorts received escalating doses of rigosertib twice daily for 14 days of a 21-day cycle. Overall, 37 patients were treated. Rigosertib exposure increased with escalating oral doses. Mean absolute oral bioavailability ranged from 13.9% (fed) to 34.8% (fasting) in 12 patients treated at the 560 mg dose level. Dose-limiting toxicity (grade 3 dysuria and shortness of breath) occurred at the 700 mg b.i.d. dose. Five patients experienced grade 3 non-haematological toxicity, including symptoms of urothelial inflammation, hypotension and syncope, fatigue and abdominal pain. Encouraging signs of clinical activity included 2 bone marrow complete remissions in refractory anaemia with excess blasts type 1 patients previously treated with azacitidine. In addition, 4 patients each achieved transfusion independence and haematological improvements. In conclusion, oral rigosertib is bioavailable and well tolerated, and has clinical activity in patients with MDS. äPhase I Clinical Trial of Oral Rigosertib in Patients with Myelodyspla(epmc).pdf DeepDyve Pubget Overpricing